Q2
CMMB — Q2 2026 Financial Report Analysis
Chemomab lost $2.2M in Q2 2026 with $6.7M of cash left (runway only into Q1 2027, going-concern warning); its future now hinges on the pending Scipher Medicine merger that would leave holders ~32% of the combined company.